Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Part 1 (SAD): SUM-191 is administrated a single dose topically. Part 2 (MAD): SUM-191 is administrated TID topically for 6 days. Part 3: SUM-191 is administrated TID topically for 6 days.”In the company’s words, NCT07565103 on ClinicalTrials.gov
- Tested for
- Bacterial Conjunctivitis
- Main trialPhase 1/2
- “This is a seamless Phase I/II, randomized, double-masked, placebo-controlled, multicenter trial to evaluate single and multiple-dose safety and tolerability of SUM-191 in healthy participants in Parts 1 (SAD) and 2 (MAD) ; and multiple-dose efficacy and safety of SUM-191 in participants with bacterial conjunctivitis in Part 3.”In the company’s words, NCT07565103 on ClinicalTrials.gov
Other drugs for Bacterial Conjunctivitis
- Fusidic Acid 1%Baxis Pharmaceuticals, Inc. · Phase 3
Coming up1
- 15 Aug 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 15 Aug 2028 | Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026